

## 2023 Independent Medical Education Call for Grant Notification

Issue Date: **Oct 4, 2023**

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

**Purpose:** As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

**Notification:** Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

**Terms and Conditions**

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must be sent exclusively to Genentech’s Independent Medical Education team. Failure to comply may automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

**Instructions**

Eligibility Criteria	<ul style="list-style-type: none"> <li>● U.S. based education provider</li> <li>● Registered account in gFRS</li> <li>● Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)</li> </ul>
Geographical Scope	<ul style="list-style-type: none"> <li>● Educational initiatives must be U.S.-based only</li> </ul>

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN will have 4 weeks to submit a grant application via the <a href="#">funding request system</a> . Please include either "Hemophilia 2023 CGN" or "PNH CGN" in the title of your CGN	November 6th, 2023
Step 2	After 2 weeks, decisions will be communicated via email.	November 20th, 2023
Step 3	Funded Project Start Date: within 10-12 weeks of grant award	Early February 2024

### Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

**Currently Available CGN Focus Area(s):**

Focus	Opportunity
<p><b>Therapeutic Area:</b> Blood Disorders</p> <p><b>Disease:</b> Hemophilia</p> <p><b>Learning Audience:</b> Community Hematologist</p> <p>Healthcare providers in hemophilia treatment centers (HTC)</p> <p>Hematologist-Oncologist</p> <p>Patients (optional)</p> <p><b>Support Available:</b> Up to \$500,000</p>	<p>Hemophilia:</p> <p>Informed physicians are essential to promoting positive patient outcomes. There is a need for accessible education targeting the early to mid-career hemophilia treatment center (HTC) workforce as well as physicians working outside of HTCs where access to education can be even more challenging.</p> <p>It is important for newer healthcare providers to understand the pharmacologic treatment modalities currently available to people living with hemophilia A so that they can provide individualized treatment plans for patients. It is also important for newer health care providers to understand the various factors contributing to care inequities in Hemophilia A including geography (rural community, distance to HTC), female gender, and mild disease.</p> <p>Genentech seeks to support independent medical education programs that focus on early to mid-career health care professionals to support their knowledge and competence of current treatment management in hemophilia A and how care inequities play a role.</p>
<p>Knowledge- and Competence-based Emerging Education</p>	<p>Paroxysmal Nocturnal Hemoglobinuria (PNH):</p> <p>Informed clinicians are essential to promoting positive patient outcomes. In recent years, the availability of new pharmacologic treatment modalities for people living with paroxysmal nocturnal hemoglobinuria (PNH) has emerged. Current and emerging treatment options present varying degrees of treatment burden and impact on quality-of-life, and introduce additional complexity in the PNH treatment landscape. The advent of new treatment options underscores the importance of ensuring clinicians are informed and incorporating the patient voice and preferences when seeking alignment in treatment decisions (i.e., shared decision making [SDM]).</p> <p>Genentech seeks independent medical education that supports clinicians ability to improve their knowledge and competence of emerging data in the context of shared decision making in PNH.</p>

Hemophilia References

1. Nationwide hematologists shortage: What's being done? [www.mdedge.com](http://www.mdedge.com). Accessed September 24, 2023.  
<https://www.mdedge.com/fedprac/avaho/article/265457/bleeding-disorders/nationwide-hematologists-shortage-whats-being-done>
2. Witkop ML, Guelcher C, Hall M, Maahs J. US haemophilia centre nurses and advanced practice providers: Demographics, roles/responsibilities, training, educational barriers and employment benefits. *The Journal of Haemophilia Practice*. 2017;4(1):14-21.  
doi:<https://doi.org/10.17225/jhp00101>
3. Soucie JM, Miller CH, Dupervil B, Le B, Buckner TW. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. *Haemophilia*. 2020;26(3):487-493. doi:<https://doi.org/10.1111/hae.13998>
4. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. *American Journal of Hematology*. 1998;59(4):288-294.  
doi:[https://doi.org/10.1002/\(sici\)1096-8652\(199812\)59:4%3C288::aid-ajh4%3E3.0.co;2-i](https://doi.org/10.1002/(sici)1096-8652(199812)59:4%3C288::aid-ajh4%3E3.0.co;2-i)
5. Lopez K, Norris K, Hardy M, Valentino LA. Defining the Impact of Social Drivers on Health Outcomes for People with Inherited Bleeding Disorders. *Journal of Clinical Medicine*. 2022;11(15):4443. doi:<https://doi.org/10.3390/jcm11154443>
6. Franchini M, Mannucci PM. The More Recent History of Hemophilia Treatment. *Seminars in Thrombosis and Hemostasis*. 2022;48(08):904-910. doi:<https://doi.org/10.1055/s-0042-1756188>
7. Haug JD. Physicians' preferences for information sources: a meta-analytic study. *Bulletin of the Medical Library Association*. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC226263/>. Published July 1997. Accessed May 3, 2019.
8. Janeve R, Desy, MD et al. Milestones and Millennials: A Perfect Pairing—Competency-Based Medical Education and the Learning Preferences of Generation Y. *Mayo Clinic Proceedings*, February 2017 DOI: [10.1016/j.mayocp.2016.10.026](https://doi.org/10.1016/j.mayocp.2016.10.026)

## PNH References

1. Kulasekararaj A and Lazana I. Paroxysmal nocturnal hemoglobinuria: Where are we going. *American Journal of Hematology*. 2023;98(54):533-543. doi:<https://doi.org/10.1002/ajh.26882>
2. Risitano A and Peffault de Latour R. How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. *British Journal of Haematology*. 2022;196:288-303.  
doi:<https://doi.org/10.1111/bjh.17753>
3. Gavriilako E, Peffault de Latour R, Risitano A. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. *Blood*. 2022;139(25):3571-82.  
doi:<https://doi.org/10.1182/blood.2021012860>